These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 14963978

  • 21. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. ESPRIT: is aspirin plus dipyridamole superior to aspirin alone in TIA or minor stroke patients?
    Rouhl RP, Lodder J.
    Expert Rev Neurother; 2008 Nov; 8(11):1661-5. PubMed ID: 18986236
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. What is the role of dipyridamole in long-term secondary prevention after an ischemic stroke or transient ischemic attack?
    Sudlow C.
    CMAJ; 2005 Oct 25; 173(9):1024-6. PubMed ID: 16247094
    [No Abstract] [Full Text] [Related]

  • 29. Antiplatelet treatment for secondary prevention of acute ischemic stroke and transient ischemic attacks: mechanisms, choices and possible emerging patterns of use.
    Moonis M, Fisher M.
    Expert Rev Cardiovasc Ther; 2003 Nov 25; 1(4):611-5. PubMed ID: 15030260
    [No Abstract] [Full Text] [Related]

  • 30. Does Aggrenox (aspirin/dipyridamole) reduce the risk of recurrent stroke to a greater degree than aspirin alone?
    Hoover PL, Mold JW.
    J Okla State Med Assoc; 2008 May 25; 101(5):80-2. PubMed ID: 18678202
    [No Abstract] [Full Text] [Related]

  • 31. [Randomized clinical study of the efficacy of buflomedil in the prevention of recurrence of cerebral ischemia in comparison with anti-platelet aggregation agents].
    De Martiis M, Parenzi A, Barlattani A, De Martiis A.
    Clin Ter; 1986 Mar 15; 116(5):367-71. PubMed ID: 3519061
    [No Abstract] [Full Text] [Related]

  • 32. The approach to optimizing stroke care.
    Panagos PD.
    Am J Emerg Med; 2008 Sep 15; 26(7):808-16. PubMed ID: 18774049
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Platelet-function inhibitors in the secondary prevention of ischemic stroke].
    Busse O, Diener HC, Grond M.
    Dtsch Med Wochenschr; 2006 Nov 15; 131 Suppl 5():S132-4. PubMed ID: 17089258
    [No Abstract] [Full Text] [Related]

  • 38. [Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial].
    Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R.
    Rev Neurol (Paris); 1982 Nov 15; 138(5):367-85. PubMed ID: 6815756
    [No Abstract] [Full Text] [Related]

  • 39. [Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].
    Diener C.
    MMW Fortschr Med; 2008 May 22; 150(21):7. PubMed ID: 18578065
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.